Skip to main content

Table 1 Number and phenotype of DCs administered

From: Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer

Median number of DCs administered per patient

    
  

no. x 106

(range)

    

DC/PC3

Selected

28.15

(23.17-37.10)

    
 

Adherence

30.73

(25.90-31.84)

    
 

p-value

>0.99

     

DC/PC3-M1

Selected

28.86

(20.49-33.85)

    
 

Adherence

26.75

(24.80-34.05)

    
 

p-value

0.80

     

Phenotype of DCs administered (median)

    
  

CD14+ (%)

(range)

CD83+ (%)

(range)

PI+ (%)

(range)

DC/PC3

Selected

2.76

(1.85-5.71)

96.18

(86.35-98.46)

7.94

(4.36-18.06)

 

Adherence

1.09

(0.82-4.41)

97.70

(90.70-98.40)

8.99

(4.81-11.50)

 

p-value

0.23

 

>.99

 

0.87

 

DC/PC3-M1

Selected

3.45

(1.15-7.9)

95.60

(85.67-98.49)

12.52

(4.34-17.09)

 

Adherence

2.04

(1.29-6.4)

98.20

(96.80-98.90)

10.10

(5.83-12.60)

 

p-value

0.87

 

0.12

 

0.72

 

Median number of DC/KLH administered per patient in all three studies

   
  

no. x 106

(range)

    
 

Selected

9.04

(5.06-17.41)

    
 

Adherence

9.86

(4.69-16.31)

    
 

p-value

0.59

     

Phenotype of DC/KLH administered in all three studies (median)

   
  

CD14+ (%)

(range)

CD83+ (%)

(range)

PI+ (%)

(range)

 

Selected

0.64

(0.01-2.00)

96.79

(92.35-99.30)

1.85

(0.92-9.30)

 

Adherence

0.36

(0-2.82)

95.69

(86.00-99.97)

1.27

(0.34-12.19)

 

p-value

0.24

 

0.55

 

0.10